Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03764956
Other study ID # IECPG/504/10/2018
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date December 26, 2018
Est. completion date December 2019

Study information

Verified date September 2019
Source All India Institute of Medical Sciences, New Delhi
Contact Sheffali Gulati, MD
Phone 9810386847
Email sheffaligulati@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the efficacy of two less restrictive dietary therapies - LGIT and MAD, used for treatment of drug resistant epilepsy in children


Description:

Up to one third of patients with epilepsy progress to drug resistant epilepsy (DRE). Current treatment options for DRE include epileptic surgery and dietary therapy. Classic KD (Ketogenic diet) is the most studied dietary therapy but the stringent restrictions and practical difficulty makes it difficult to follow. So less restrictive diets like MAD and LGIT were introduced. These are reported to have less adverse effects also. But no published study has ever been conducted comparing these two diets head to head.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date December 2019
Est. primary completion date December 2019
Accepts healthy volunteers No
Gender All
Age group 1 Year to 15 Years
Eligibility Inclusion Criteria:

- Children aged 1-15 years with drug resistant epilepsy

- Willing to come for regular follow-up according to study protocol Drug resistant epilepsy defined as

- Seizure frequency >4 seizures per month, while on optimal doses of at least 2 prescribed antiepileptic drugs

- For West syndrome, drug resistant epilepsy will be defined as more than 4 clusters of spasms per month despite treatment with antiepileptic drugs and either ACTH(Adrenocorticotrophic hormone) or Vigabatrin

Exclusion Criteria:

- Surgically remediable causes for DRE

- Inborn errors of metabolism

- Previously received KD, MAD or LGIT

- Known case of

1. Chronic kidney disease

2. Chronic liver disease/GI illness

3. Congenital/acquired heart disease

4. Chronic respiratory illness

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Low glycemic Index Therapy (LGIT)
Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only. For this purpose, various dietary menus will be provided to the parents.
Modified Atkins Diet (MAD)
Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio. For this purpose, various dietary menus will be provided to the parents.

Locations

Country Name City State
India AIIMS New Delhi Delhi
India All India Institute of Medical Sciences New Delhi Delhi

Sponsors (1)

Lead Sponsor Collaborator
All India Institute of Medical Sciences, New Delhi

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of seizure reduction from baseline at 24 weeks of therapy Mean weekly seizure reduction at 24 weeks divided by Mean weekly seizure measured at baseline multiplied by 100 At the end of 24 weeks of dietary therapy
Secondary Proportion of children who achieve >50% seizure reduction Number of children with >50% reduction divided by number of children in each arm At the end of 24 weeks of dietary therapy
Secondary Incidence of adverse events Routine hemogram, Renal function test (RFT), Liver function test (LFT) and lipid profile will be assessed for any alterations. Adverse events, vomiting, constipation and diarrhea will be checked by parents record At the end of 24 weeks of dietary therapy
Secondary Compliance of participants with dietary therapy in each arm will be determined each week, whether satisfactory or unsatisfactory Weekly compliance assessment of each participant will be done At the end of 24 weeks of dietary therapy
Secondary Change in Social quotient(SQ) with each dietary therapies Proportion of children with improvement in Social quotient (SQ) assessed by Vineland Social Maturity Scale (VSMS) at 24 weeks. VSMS consists of 8 subsets - Communication skills, General self-help ability, Locomotion skills, Occupation skills, Self-direction, Self-help eating, Self-help dressing, Socialization skills. Social age is calculated by adding the scores of all subsets. Social quotient (SQ) is calculated by social age divided by chronological age multiplied by 100. At the end of 24 weeks of dietary therapy
Secondary Change in Quality of Life of participants who are less than 4 years of age at 24 weeks as compared to baseline In children less than 4 years quality of life is assessed by PedsQL (Pediatric Quality of life inventory). PedsQL consists of 21 questions each having 5 responses with scores 0,1,2,3 and 4. Minimum score is 0 and maximum is 84. Quality of life is poor with larger score. At the end of 24 weeks of dietary therapy
Secondary Change in Quality of Life of participants who are more than or equal to 4 years of age at 24 weeks as compared to baseline In children with age 4 years or more, QOLCE 55 (Quality of life in childhood epilepsy questionnaire) is used to assess quality of life. QOLCE 55 consists of 55 questions which are classified into 4 categories. Each question have 5 responses with scores as 0,25,50,75 and 100. Mean score of each category is calculated and final score calculated by mean of the scores of 4 categories. Minimum score is 0 and maximum is 100. Quality of life is better with larger score. At the end of 24 weeks of dietary therapy
Secondary Change in Quality of Life of caregivers at 24 weeks as compared to baseline Quality of life of caregivers is assessed by WHOQOL-BREF. WHOQOL BREF contains 26 items categorized into 4 domains. For each question response is scored 1,2,3,4 or 5. Total raw score is then calculated and is converted to transformed score. Minimum score is 0 and maximum is 100. Quality of life is poor with smaller score. At the end of 24 weeks of dietary therapy
Secondary Gut microbiota (GM) analysis pre and post dietary therapy Changes in percentage distribution of various micro organisms in gut microbiota after dietary therapy as compared to baseline GM At the end of 24 weeks of dietary therapy
Secondary Change in behavioral abnormalities with each dietary therapy Behavior assessment is done using Child behavior check list (CBCL).This questionnaire contains 100 and 113 questions for age groups of 1 ½ - 5 years and 6-18 years respectively. Score of 2 will be given for a response of 'very true', 1 for a response of 'somewhat true' and 0 for 'not true'. Total score is obtained by adding all the subsets. Subsets for age 1.5 years to 5 years include - Emotionally reactive, anxious/depressed, somatic complaints, withdrawn, sleep problems, attention problems, aggressive behavior and other problems. Subsets for age 6 years to 12 years include - Anxious/Depressed, withdrawn, somatic complaints, social problems, thought problems, attention problems, rule breaking behavior, aggressive behavior, other problems. Raw score is then converted to T score according to the published charts. Minimum T score is 28 and maximum is 100. Larger score indicates more behavioral problems. At the end of 24 weeks of dietary therapy
See also
  Status Clinical Trial Phase
Completed NCT04378075 - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Phase 2/Phase 3
Recruiting NCT05928598 - Goals for Epilepsy Clinic Visits Trial N/A
Recruiting NCT05539287 - Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy Phase 2
Not yet recruiting NCT04601974 - Lentiviral Gene Therapy for Epilepsy Phase 1/Phase 2
Completed NCT02982824 - Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy N/A
Recruiting NCT05485558 - the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy Phase 2
Not yet recruiting NCT04553354 - Cortical Resections in Drug Resistant Epilepsy
Recruiting NCT04999046 - NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy N/A
Recruiting NCT04714996 - Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy Phase 2
Recruiting NCT04839601 - RNS System RESPONSE Study N/A
Recruiting NCT06059157 - Epileptogenic Network Visualisation With Advanced MRI N/A
Recruiting NCT05947656 - Evaluation of the NaviFUS System in Drug Resistant Epilepsy N/A
Recruiting NCT05393518 - Electroclinical Correlation of Anxiety N/A
Not yet recruiting NCT05555537 - MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy
Completed NCT03419000 - Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY N/A
Enrolling by invitation NCT06341075 - Real-World Study of Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Drug-resistant Epilepsy N/A
Not yet recruiting NCT05527093 - Cartography of Social Cognition Network and Their Alterations in Patients With Epilepsy N/A
Recruiting NCT05697614 - The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children Phase 4
Recruiting NCT06309251 - Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Recruiting NCT06432907 - StereoEEG Motor Neuronal Potentials Decoding N/A